Search | Clinical Trials Finder

Conditions: Fever
Interventions: Intravenous Ibuprofen, Acetaminophen (Standard of Care); Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Intracerebral Haemorrhage, Intraventricular
Interventions: Pioglitazone 15mg; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: COVID-19
Interventions: PF-06650833, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: CoronaVirus Induced Disease-2019 (COVID-19)
Interventions: Ibrutinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Stanford, California • Washington D.C., District of Columbia • Ft. Pierce, Florida + 4 more

Conditions: Acute Cerebrovascular Accident, Cerebral Edema
Interventions: Diphenhydramine, Pantoprazole, Famotidine, Dextromethorphan; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Enteral Tube Placement
Interventions: enteral tube placement accuracy, NEM method for NG/OG tube placement; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 6 Months
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Nasogastric Tube Placement
Interventions: Nasotrak System; Device
Lead sponsor: Nasotrak Medical Pte Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Fort Wayne, Indiana • New York, New York

Conditions: Critical Illness
Interventions: Ultrasound; Diagnostic Test
Lead sponsor: Joseph D. Tobias; Other
Eligibility: Up to 18 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy Subjects
Interventions: Isavuconazonium sulfate IV, Isavuconazonium sulfate capsules; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Establish Normative pH Values in Neonates
Interventions: RightSpot Infant pH Indicator; Device
Lead sponsor: RightBio Metrics; Industry
Eligibility: 24 Weeks to 40 Weeks
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Adhesive Small Bowel Obstruction
Interventions: Gastrografin, Saline, SBO Treatment Without NG Tubes; Drug · Procedure
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Small Bowel Obstruction, Ileus
Interventions: No clamp trial, Clamp trial; Other
Lead sponsor: University of Illinois College of Medicine at Peoria; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Peoria, Illinois

Conditions: COVID-19
Interventions: Niclosamide, Placebo; Drug
Lead sponsor: NeuroBo Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Sheffield, Alabama • Irvine, California • Jacksonville, Florida + 5 more

Conditions: Autosomal Recessive Polycystic Kidney (ARPKD)
Interventions: Tolvaptan Suspension, Tolvaptan Tablets; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 28 Days to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 9 more

Conditions: Small Bowel Obstruction, Gastrointestinal Hemorrhage
Interventions: RightSpot pH Indicator, Chest radiograph; Device · Radiation
Lead sponsor: RightBio Metrics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Ileus
Interventions: chewing gum; Other
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Nasogastric Tube
Interventions: Nasogastric Tube; Device
Lead sponsor: Gravitas Medical, Inc.; Industry
Eligibility: 0 Weeks to 18 Weeks
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Infection
Interventions: Grapefruit Juice; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gastrointestinal Complication
Interventions: PrevisEA device; Device
Lead sponsor: Entac Medical Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 8
States / cities: Orlando, Florida • Chicago, Illinois • Grand Rapids, Michigan + 5 more

Conditions: Solid Tumor
Interventions: Sirolimus, Cyclophosphamide, Etoposide, Celecoxib; Drug
Lead sponsor: Emory University; Other
Eligibility: 1 Year to 30 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 5
States / cities: Atlanta, Georgia • St Louis, Missouri • Pittsburgh, Pennsylvania + 1 more

Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Histiocytic Sarcoma, Juvenile Xanthogranuloma, Langerhans Cell Histiocytosis, Malignant Glioma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Glioma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Rhabdoid Tumor, Stage III Osteosarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Osteosarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Stage IVA Osteosarcoma AJCC v7, Stage IVB Osteosarcoma AJCC v7, Wilms Tumor
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Erdafitinib, Ivosidenib, Laboratory Biomarker Analysis, Larotrectinib Sulfate, Magnetic Resonance Imaging, Mutation Carrier Screening, Olaparib, Palbociclib, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib, X-Ray Imaging; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 1,377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 168
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 126 more

Conditions: COVID-19
Interventions: Duvelisib, Peripheral blood draw, Placebo; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Relative Bioavailability
Interventions: Tebipenem tablet form, Tube feeds; Drug · Other
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 120 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Hemophagocytic Lymphohistiocytosis
Interventions: Ruxolitinib, Dexamethasone, Etoposide; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 6 Weeks to 22 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 13
States / cities: Phoenix, Arizona • Orange, California • San Francisco, California + 10 more

Search by objective public record fields.

Aggressive Fever Control With Intravenous Ibuprofen After Non-traumatic Brain Hemorrhage

Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone

IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)

Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury

Histamine Glutamate Antagonism in Stroke

Nasogastric/Oral Gastric Tube Placement in Infants: Comparing 2 Measurement Methods

A Clinical Study to Evaluate the Ultrasonic Detection of a Novel Nasogastric Tube in the Human Body.

Gastric Ultrasound in Tube Fed Intubated Patients

A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants

Product Validation Study of RightSpot Infant pH Indicator for Rapid Bedside Verification of Proper Nasogastric (NG) Tube Placement in Newborn Intensive Care (NICU) Patients

Optimizing Treatment of Adhesive Small Bowel Obstruction

Nasogastric Tube Clamping Trial vs. Immediate Removal

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Nasogastric/Orogastric Tube Placement Verification Study Using RightSpot pH Indicator to Verify Gastric Acidity

Does Chewing Gum After Elective Laparoscopic Colectomy Surgery Decrease Ileus?

Gravitas Feeding Tube System Placement in Neonates

Gastrointestinal Implications of Voriconazole Exposure

Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment

Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Duvelisib to Combat COVID-19

Bioavailability of Tebipenem (SPR994) Crushed Tablet

Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis